Corona virus vaccine

Worldwide many research centers are on their race to find Corona virus vaccine. Who will be on the finish line and when?

More than 100+ countries are conducting their pre-clinical trails on the Corona virus vaccine, more than 70 countries are being tracked down by world health organization (WHO). Dozens of Corona virus vaccine are on their clinical trails for vaccine development phases.

Here are some of the research centers around the world working faster for Corona virus vaccine development.


Located in England oxford university has conducted its clinical trails on covid vaccine and published the results of the phase I/II trail. It state that the vaccine produces strong immune response.

Professor pollard says “The phase I/II data for our corona virus vaccine”, shows that the vaccine did not lead to any unexpected reaction and had a similar safety profile to previous vaccines of this type.

The immune responses observed following vaccination are in line with what previous animal studies have shown are associated with protection against the SARS-COV-2 virus. Although we must continue with our rigorous clinical trail programme to confirm this in human”.

Corona virus vaccine


Pfizer and biontech university which is located in new York has announced an agreement with U.S government for up to 600 million doses of MRNA- based vaccine candidate against SARS-COV-2.

The US government has also agreed to pay $1.95 billion for first 100 million doses following FDA authorization approval.

Corona virus vaccine


It is an American biotechnology company whose headquarters are in Massachusetts, united states.
Moderna Inc’s covid vaccine could be ready by the end of this year.
It has never brought a vaccto market and is receiving nearly $1 billion for the government to speed up the process of vaccine testing.
It will start of a 30,000 subject trail to demonstrate it is safe and effective.

Corona virus vaccine


It is a Chinese university whose headquarters are in tianjin, China. It has got promising phase 2 results of covid-19 vaccine.

candidate which resulted safe and immune inducing in mid-stage clinical study.

In phase 2, cansino test of AD5-ncov, in 508 healthy candidates aged 18 years or older has neutralized antibody responses to SARS-COV-2.

Nevertheless, the results are promising and warrant studies with more participants. Longer observation of antibody levels and multiple vaccine doses given the urgent need for a COVID-19 vaccine.

Since CanSino is the first company to publish Phase 2 results. They have observed how the level of antibodies, T-cells were compared to results of COVID-19 vaccine candidates from other companies.

However, it is still unclear which antibody levels will provide protection against SARS-CoV-2 and for how long this protection will last” Say’s Rosenbaum.

Corona virus vaccine

5 ICMR( indian counselling of medical research)

ICMR situated in Delhi, India is also on its way to develop vaccine for covid-19.
As India being one of the largest vaccine producers in the world is working fast to vaccine development process.

Human clinical trials for a vaccine on Covid-19, initiated in the country with approximately 1,000 volunteers participating in the exercise, for each of the two ingenuously developed vaccine candidates, the ICMR said on Tuesday.

Corona virus vaccine


Imperial college is a public research university in London. Imperial college has received more then £41 million in funding from the UK government and further £5 million in philanthropic donations.

The companion’s epidemiologists are informing policymakers worldwide. This virologists are trialing their COVID-19 vaccine. Respiratory specialists are helping understand the progression of the virus and why it hits some patients harder. Biomedical engineers have developed rapid result corona virus tests. Data scientists, AI researchers and health economists are among the many Imperial researchers redeploying their expertise to fight the pandemic. And a multidisciplinary team has also set out key regulations. Innovators must comply with when designing and building technologies safely to tackle COVID-19. Says imperial college of London


It is also a Chinese university based in Beijing, China. On July 3, 2020, the Brazilian national regulator agency. anvisa granted approval to a phase III clinical trail of the covid-19 vaccine sponsored by institute butanitan.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, “We are pleased to advance to Phase III trials with Butantan, which will allow us one step further to our commitment to developing vaccines for global use and to our mission of supplying vaccines to eliminate human diseases.”


It is an american base company, headquarters of Inovio Plymouth meeting is in Pennsylvania, united States.
The advantage of INOVIO’S DNA medicine are how fast DNA medicines can be designed and manufacture. The stability of the products which do not require freezing in storage and transport and the robust immune response.

INO-4800 covid-19 DNA vaccine once inside the cell, the plasmids begin replicating, thereby strengthening the body’s own natural response mechanism.

Who will be the winner in the race of covid-19 vaccine development

There are many different vaccines developed around the world for covid-19. It is sure that there will be covid-19 vaccine by the end of 2020.

The vaccine normally takes around 8 to 15 years to be invented and brought to sale.
The fastest vaccine which was developed till now took 5 years.

Experts say however it is still not yet to be decide which country will produce the vaccine first but whoever produces should be selling the vaccine on non-profit business base.

If you are looking for job then click here JOBSEEKERS.

Leave your thoughts

CommentLuv badge

Our main aim is to assist people who are searching for jobs to get the job the love and desire


Contact us on: Job_seekers12 on Instagram

Job seekers on Facebook